Clinical trials: Skin Tumors
Breast Cancer
XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer.
- Trial name
- NCT01777945
- Testing
- capecitabine, docetaxel
- Where
- 14 sites in Hungary
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER…
- Trial name
- NCT00234403
- Testing
- gefitinib and fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Actinic Keratosis
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
The main purpose of this trial is to demonstrate the predictive value of the clinical diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using histopathological examination as the standard.
- Trial name
- NCT01892137
- Testing
- Ingenol mebutate gel 0.05%
- Where
- 10 sites in Australia, Germany
- Volunteers
- 137 people
- Sponsor
- LEO Pharma
Breast Cancer, Pharmacokinetics
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
The purpose of this study is to evaluate the pharmacokinetic (PK) profile of a fixed dose of SPI-2012 in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) chemotherapy, as measured by the serum…
- Trial name
- NCT03135951
- Testing
- SPI-2012
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Breast Cancer
A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
Currently, if a radiologist finds a suspicious lesion seen only on a diagnostic Contrast Enhanced Digital Mammography (CEDM) exam requiring biopsy the biopsy procedure would likely be performed with MRI guidance because there are…
- Trial name
- NCT04671329
- Testing
- Affirm Contrast Biopsy procedure
- Where
- 2 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Hologic, Inc.
Breast Neoplasms
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
- Trial name
- NCT02771795
- Testing
- Herceptin (trastuzumab), SB3 (proposed trastuzumab biosimilar)
- Where
- 40 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 538 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Breast Cancer
CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
The goal of this clinical research study is to study the drug CNF2024 as a single agent or in combination with trastuzumab in patients with advanced breast cancer and to: find the highest dose of the drug CNF2024 as a single…
- Trial name
- NCT00412412
- Testing
- CNF2024, CNF2024 + trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Biogen
Breast Cancer
A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer
This is a non-randomized Phase 2 study testing pemetrexed and doxorubicin in combination for locally advanced or metastatic breast cancer.
- Trial name
- NCT00102219
- Testing
- Pemetrexed, Doxorubicin
- Where
- 12 sites in Brazil, Greece and 5 more
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Melanoma
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma
This is a Phase II, non-randomized, open label study of ILX651 in patients with inoperable locally advanced or metastatic melanoma. Approximately 60 patients will be enrolled in this study that is expected to last 18 months.
- Trial name
- NCT00068211
- Testing
- ILX651
- Where
- 19 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Skin Cancer, Melanoma of Skin
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
DERM is a Medical Device that uses artificial intelligence to help doctors check if a skin lesion might be cancerous. It works by analysing close-up pictures of skin lesions taken with a smartphone.
- Conditions
- Skin Cancer, Melanoma of Skin, Squamous Cell Cancer, Basal Cell Cancer
- Trial name
- NCT06654999
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- 3 sites in United Kingdom
- Volunteers
- 115 people
- Sponsor
- Skin Analytics Limited
Triple-negative Breast Cancer
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced…
- Trial name
- NCT03499899
- Testing
- LAG525, PDR001, Carboplatin
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Role of Early Versus Late Switch to Lapatinib-Capecitabine
The study will be conducted as a multicenter prospective observational cohort study, trying to cover almost all Brazilian States, in a population of ErbB2 positive metastatic breast cancer patients, whose disease has progressed…
- Trial name
- (TYCO1) (NCT01357863)
- Testing
- Treatment
- Where
- 13 sites in Brazil
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no…
- Trial name
- ICEBERG 1 (NCT00494234)
- Testing
- Olaparib
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Malignant Melanoma
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases.
- Trial name
- NCT01253564
- Testing
- RO5185426
- Where
- 2 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts.
- Trial name
- NCT00609011
- Testing
- MPC-6827 + Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Myrexis Inc.
Breast Neoplasms
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone…
- Trial name
- NCT02258464
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Background hormonal therapy
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Skin Condition, Skin Diseases
VIO Imaging for Skin Tissue Assessment (VISTA)
To demonstrate the safety and effectiveness of the VIO device in obtaining in vivo images that show tissue features including epidermis, dermis, collagen, blood vessels, and/or pigment.
- Conditions
- Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities
- Trial name
- VISTA (NCT05619471)
- Testing
- VIO Imaging
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Enspectra Health
Breast Cancer
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer.
- Trial name
- NCT00190671
- Testing
- pemetrexed, cyclophosphamide
- Where
- 13 sites in Austria, Czechia and 4 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Neoplasm of Skin
Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer
This case series will assess the use of suction blister epidermal grafts harvested by a novel device on select patients that have wounds from Mohs or excisional surgery.
- Trial name
- NCT01536444
- Testing
- Momelan Technologies Epidermal Graft Harvesting System
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Momelan Technologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.